Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
about
G-CSF and GM-CSF in NeutropeniaThe Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European CountriesBarriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.Biosimilars: Hope and concern.Can biosimilars help achieve the goals of US health care reform?Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte-colony-stimulating factor: safety, efficacy, and graft performance.Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz.Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropeniaThe role of biosimilars in value-based oncology care
P2860
Q26800954-38E78D7D-35D2-46B4-AEA2-3E5BA5E8404AQ33665611-950DDB33-37C9-45E0-9D9A-E34BB80AC763Q37731321-A700FAD4-9084-4637-BBD6-844074482979Q37737572-82849D8D-71EF-469C-9D9B-C9C7AAE90504Q38590668-C3981FBA-992B-4350-B7B9-B3BDFB273399Q38670950-2AB99EEA-2699-493E-9DF7-387EA6BBA884Q38893192-62B18A8B-76BE-4F07-8961-167ECF61276CQ39385304-A525C102-9729-45AC-8ECF-293FA92CA5DBQ39504419-FE55C7FF-B997-4DB0-8382-901B1F842543Q40141879-9F88F21A-CE8B-46D1-A773-BF1D3E3BD596Q47908189-4A675010-D3C9-49AF-8F23-FCCF6E8A3B76Q47965968-39323F83-7819-4B6F-9618-88BDED72FDEBQ58558564-24B2D69D-85D0-4785-89FF-3BE077596FB4Q58605622-EE65AFD9-F891-445B-97E7-72A81FED864E
P2860
Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Potential cost savings from ch ...... countries: a simulation study.
@ast
Potential cost savings from ch ...... countries: a simulation study.
@en
type
label
Potential cost savings from ch ...... countries: a simulation study.
@ast
Potential cost savings from ch ...... countries: a simulation study.
@en
prefLabel
Potential cost savings from ch ...... countries: a simulation study.
@ast
Potential cost savings from ch ...... countries: a simulation study.
@en
P2093
P1476
Potential cost savings from ch ...... countries: a simulation study.
@en
P2093
Ahmed Altyar
Ivo Abraham
Karen MacDonald
Tri Murti Andayani
P304
P356
10.1016/J.CLINTHERA.2015.01.011
P577
2015-02-20T00:00:00Z